VIDEO: Visus shares phase 2 results of presbyopia drop formulations

ByDavid W. Mullin

ByBen Bergo

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WASHINGTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Ben Bergo, CEO of Visus Therapeutics, discusses the results of the VIVID phase 2 study of presbyopia drop formulations in patients with emmetropic presbyopia.